Anavex Life Sciences Corporation
NASDAQ:AVXL 4:00:00 PM EDT
Earnings Announcements
Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates
Published: 12/28/2020 12:09 GMT
Anavex Life Sciences Corporation (AVXL) - Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results and Clinical Program Updates.
Anavex Life Sciences Corp - Plan to Advance Avatar Adult Rett Syndrome Study Into a Pivotal Phase 2/3 Clinical Trial.
Anavex Life Sciences Corp - Plan to Advance Avatar Adult Rett Syndrome Study Into a Pivotal Phase 2/3 Clinical Trial.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.19
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.19
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.19
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.19
More details on our Analysts Page.